This clinical trial is focused on studying certain types of cancer known as fusion-driven sarcomas. These are rare cancers that can spread to other parts of the body, a process known as metastasis. The specific types of sarcomas being studied include Ewing sarcoma, alveolar rhabdomyosarcoma, and synovial sarcoma. The trial is designed for patients who have already undergone standard treatments and are in a state of either complete or partial remission, meaning the cancer has either disappeared or reduced in size.
The treatment being tested in this study is an IPX vaccine, which is an emulsion for injection. This vaccine is made up of specific proteins, including PERVI-FUS, PERVI-NEO, and 11902A. The purpose of the study is to see if this vaccine can help the body’s immune system, particularly T-cells, to respond to the cancer. T-cells are a type of white blood cell that play a crucial role in the immune response. The study will compare the effects of the vaccine to a placebo, which is a substance with no active ingredients.
Participants in the study will receive the vaccine over a period of time, with the maximum treatment period being 113 days. The study will monitor the participants’ immune response to the vaccine, as well as their overall health and quality of life during the treatment. The primary goal is to determine if the vaccine can successfully induce a T-cell response without causing unacceptable side effects. The study will also look at other factors, such as the participants’ event-free survival and overall survival at 180 days after the start of the study.



Germany